Clinical trials: Endocrine Disorder
Type 1 Diabetes Mellitus
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
This study is constituted of 2 parts: Part A: A total of 36 patients will be enrolled in part A. Each eligible subject will participate in two 14-day treatment periods with Continuous Subcutaneous Insulin Infusion (CSII) of…
- Trial name
- NCT02562313
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Adocia
Breast Cancer
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
This is a phase III clinical trial to evaluate the efficacy and safety of BPI-16350 in combination with Fulvestrant versus placebo combined with Fulvesrant in Patients who have HR positive and HER2 negative locally…
- Trial name
- NCT05433480
- Testing
- BPI-16350, Fulvestrant
- Where
- 64 sites in China
- Volunteers
- 274 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Diabetes Mellitus, Type 1
A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus
The purpose of this research study is to look at concentrations of GSK189075 in blood when single doses of the drug are taken by mouth in combination with basal insulin.
- Trial name
- NCT00575159
- Testing
- GSK189075
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
The purpose of this study is to evaluate the glucodynamic effects of dulaglutide in Japanese participants with type 2 diabetes mellitus.
- Trial name
- NCT03315780
- Testing
- Dulaglutide
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of…
- Trial name
- NCT07843862
- Testing
- HRS-4729 Injection, Mazdutide
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Ovarian Cancer
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors.
- Trial name
- BOUQUET (NCT04931342)
- Testing
- Ipatasertib, Cobimetinib, Trastuzumab Emtansine
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 176 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes
Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 Diabetes
This early feasibility first-in-human study is a prospective single-arm single-center study of Sigi insulin patch pump. After a 1st day and night under medical surveillance during a hotel stay, Sigi system will be evaluated…
- Trial name
- SigiFIH (NCT05973422)
- Testing
- SIGI Insulin Management System
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes
Diabetes-specific Formulas on Nutritional Outcomes in Individuals With Diabetes Who Require Nutritional Support
The study aims to demonstrate the non-inferiority of diabetes-specific formula (DSF)1 compared to DSF2 in individuals with type 1 diabetes, type 2 diabetes or prediabetes and who are at nutritional risk.
- Trial name
- NCT06632002
- Testing
- DSF1, DSF2, Standard of Care (SOC)
- Where
- Taiwan
- Volunteers
- 103 people
- Sponsor
- Abbott Nutrition
Diabetes Mellitus, Type 2
To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.
This trial was designed to compare meal related inhalation of Technosphere/Insulin to subcutaneous regular insulin in patients with type 2 diabetes.
- Trial name
- NCT00419302
- Testing
- Technosphere/Insulin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Mannkind Corporation
Diabetic Kidney Disease
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
- Trial name
- NCT02509624
- Testing
- Selonsertib
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Advanced Cancer, Pancreatic Cancer
A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer
This is a 2-phase study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and gemcitabine. The study has 2 parts.
- Trial name
- NCT00862524
- Testing
- ARRY-334543, EGFR/ErbB2 inhibitor; oral, Gemcitabine, nucleoside analogue; intravenous
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Array BioPharma
Type 2 Diabetes Mellitus
Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.
- Trial name
- NCT02786979
- Testing
- Beraprost, Aspirin
- Where
- 6 sites in China
- Volunteers
- 190 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus
Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use
This post marketing surveillance study aims to monitor the safety and efficacy of ONGLYZA under conditions of actual use in patients who are diagnosed with diabetes mellitus type 2 and are prescribed ONGLYZA by their physician.
- Trial name
- ONGLYZA PMS (NCT01223456)
- Where
- 11 sites in Philippines
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of TI Inhalation Power in combination with a basal insulin versus insulin aspart in combination with a basal insulin
- Trial name
- NCT01445951
- Testing
- Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
- Where
- 90 sites in United States, Brazil and 2 more
- Volunteers
- 518 people
- Sponsor
- Mannkind Corporation
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in…
- Trial name
- NCT01835431
- Testing
- insulin degludec/insulin aspart, insulin aspart, insulin detemir
- Where
- 73 sites in United States, Belgium and 13 more
- Volunteers
- 362 people
- Sponsor
- Novo Nordisk A/S
Advanced Breast Cancer
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
- Trial name
- VERITAC-2 (NCT05654623)
- Testing
- ARV-471, Fulvestrant
- Where
- 312 sites in United States, Argentina and 29 more
- Volunteers
- 624 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment
Primary Objective: To demonstrate the superiority of insulin glargine over insulin NPH (Neutral Protamin Hagedornon) the change in HbA1c from baseline to the end of the treatment period.
- Trial name
- LANCELOT (NCT00949442)
- Testing
- Insulin Glargine (HOE901) [Lantus], Glimepiride, human insulin [NPH]
- Where
- 87 sites in Brazil, Czechia and 15 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
Diabetic Foot, Diabetic Foot Ulcer
SkinTE™ in the Treatment of Diabetic Foot Wounds
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on a commercially available human autologous homologous skin construct with SOC dressing compared to SOC dressings…
- Conditions
- Diabetic Foot, Diabetic Foot Ulcer, Ulcer Foot
- Trial name
- NCT03881254
- Testing
- Human Autologous Homologous Skin Construct, Additional Outer Dressing Applicaiton, Offloading
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- PolarityTE
Solid Tumors Harboring NTRK Fusion
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- NAVIGATE (NCT02576431)
- Testing
- BAY2757556 (Larotrectinib, Vitrakvi)
- Where
- 98 sites in United States, Argentina and 23 more
- Volunteers
- 215 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.